RSS-Feed abonnieren
DOI: 10.3415/VCOT-10-10-0142
Osteogenic differentiation of equine cord blood multipotent mesenchymal stromal cells within coralline hydroxyapatite scaffolds in vitro
Publikationsverlauf
Received:
05. Oktober 2010
Accepted:
05. Juni 2011
Publikationsdatum:
17. Dezember 2017 (online)
Summary
Objective: To investigate the osteogenic differentiation potential of equine umbilical cord blood-derived multipotent mesenchymal stromal cells (CB-MSC) within coralline hydro-xyapatite scaffolds cultured in osteogenic induction culture medium.
Methods: Scaffolds seeded with equine CBMSC were cultured in cell expansion culture medium (control) or osteogenic induction medium (treatment). Cell viability and distribution were confirmed by the MTT cell viability assay and DAPI nuclear fluorescence staining, respectively. Osteogenic differentiation was evaluated after 10 days using reverse transcription polymerase chain reaction, alkaline phosphatase activity, and secreted osteocalcin concentration. Cell morphology and matrix deposition were assessed by scanning electron microscopy (SEM) after 14 days in culture.
Results: Cells showed viability and adequate distribution within the scaffold. Successful osteogenic differentiation within the scaffolds was demonstrated by the increased expression of osteogenic markers such as Runx2, osteopontin, osteonectin, collagen IA increased levels of alkaline phosphatase activity increased osteocalcin protein secretion and bone-like matrix presence in the scaffold pores upon SEM evaluation.
Clinical significance: These results demonstrate that equine CB-MSC maintain viability and exhibit osteogenic potential in coralline hydroxyapatite scaffolds when induced in vitro. Equine CB-MSC scaffold constructs deserve further investigation for their potential role as biologically active fillers to enhance bone-gap repair in the horse.
-
References
- 1 Kraus KH, Kirker-Head C. Mesenchymal stem cells and bone regeneration. Vet Surg 2006; 35: 232-242.
- 2 Vertenten G, Gasthuys F, Cornelissen M. et al Enhancing bone healing and regeneration: present and future perspectives in veterinary orthopaedics. Vet Comp Orthop Traumatol 2010; 23: 153-162.
- 3 Horner EA, Kirkham J, Wood D. et al Long bone defect models for tissue engineering applications: Criteria for choice. Tissue Eng Part B 2010; 16: 263-271.
- 4 Konttinen Y, Waris E, Xu J. et al Bone grafting. Curr Othop 1998; 12: 209-215.
- 5 Drosse I, Volkmer E, Capanna R. et al Tissue engineering for bone defect healing: An update on a multi-component approach. Injury 2008; 39 S (02) S9-S20.
- 6 Koch TG, Heerkens T, Thomsen PD. et al Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol 2007; 7: 26
- 7 Berg LC, Koch TG, Heerkens T. et al Chondrogenic potential of mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood. Vet Comp Orthop Traumatol 2009; 22: 363-370.
- 8 Koch TG, Thomsen PD, Betts DH. Improved isolation protocol for equine cord blood-derived mesenchymal stromal cells. Cytotherapy 2009; 11: 443-447.
- 9 Reed SA, Johnson SE. Equine umibilical cord blood contains a population of stem cells that express Oct4 and differentiate into mesodermal and endodermal cells types. J Cell Physiol 2008; 215: 329-336.
- 10 Toupadakis CA, Wong A, Genetos DC. et al Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue. Am J Vet Res 2010; 1: 1237-1245.
- 11 Koblas T, Harman SM, Saudek F. The application of umbilical cord blood cells in the treatment of diabetes mellitus. Rev Diabet Stud 2005; 2: 228-234.
- 12 Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007; 96: 1020-1024.
- 13 Ryan JM, Barry FP, Murphy JM. et al Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005; 2: 8
- 14 Stojko R, Witek A. Umbilical cord blood stem cells. Pol J Gyn Invest 2006; 9: 35-38.
- 15 Damien E, Revell A. Coralline hydroxyapatite bone graft substitute: A review of experimental studies and biomedical applications. J Appl Biomat Biom 2004; 2: 65-73.
- 16 Wasielewski RC, Sheridan KC, Lubbers MA. Coral-line hydroxyapatite in complex acetabular reconstruction. Orthopedics 2008; 31: 367
- 17 Pfaffl M, Tichopad A, Prgomet C. et al Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – excel-based tool using pair-wise correlations. Biotechnol Lett 2004; 26: 509-515.
- 18 Vunjak-Novakovic G. The fundamentals of tissue engineering: Scaffolds and bioreactors. Novartis Found Sym 2003; 249: 34-46.
- 19 Freshney RI. Basic Principles of Cell Culture. In Culture of Cells for Tissue Engineering. VunjakNovakovic G, Freshney RI. editors.. New Jersey; John Wiley & Sons, Inc; 2006. pg 3-22.
- 20 Choi KM, Seo YK, Yoon HH. et al Effect of ascorbic acid on bone marrow-derived mesenchymal stem cell proliferation and differentiation. J Biosci Bioeng 2008; 105: 586-594.
- 21 Nair MB, Suresh Babu S, Varma HK. et al A trip-hasic ceramic-coated porous hydryoxyapatite for tissue engineering application. Acta Biomater 2008; 4: 173-181.
- 22 Wang H, Li Y, Zuo Y. et al Biocompatibility and osteogenesis of biomimetic nano-hydroxyapatite/ polyamide composite scaffolds for bone tissue engineering. Biomaterials 2007; 28: 3338-3348.
- 23 Oliveira JM, Rodrigues MT, Silva SS. et al Novel hydroxyapatite/chitosan bilayered scaffold for osteochondral tissue-engineering applications: Scaffold design and its performance when seeded with goat bone marrow stromal cells. Biomaterials 2006; 27: 6123-6137.
- 24 Mygind T, Stiehler M, Baatrup A. et al Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials 2007; 28: 1036-1047.
- 25 Degistirici Ö, Jäger M, Knipper A. Applicability of cord blood-derived unrestricted somatic stem cells in tissue engineering concepts. Cell Prolif 2008; 41: 421-440.
- 26 Vidal MA, Kilroy GE, Lopez MJ. et al Characterization of equine adipose tissue-derived stromal cells: Adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg 2007; 36: 613-622.
- 27 Zhu J, Sasano Y, Takahashi I. et al Temporal and spatial gene expression of major bone extracellular matrix molecules during embryonic mandibular osteogenesis in rats. Histochem J 2001; 33: 25-35.
- 28 Dalby MJ, McCloy D, Robertson M. et al Osteoprogenitor response to semi-ordered and random nanotopographies. Biomaterials 2006; 27: 2980-2987.
- 29 Beck GR. Inorganic phosphate as a signalling molecule in osteoblast differentiation. J Cell Biochem 2003; 90: 234-243.
- 30 Meinel L, Karageorgiou V, Fajardo R. et al Bone tissue engineering using human mesenchymal stem cells: Effects of scaffold material and medium flow. Ann Biomed Eng 2004; 32: 112-122.
- 31 Du D, Furukawa K, Ushida T. Oscillatory perfusion seeding and culturing of osteoblast-like cells on porous beta-tricalcium phosphate scaffolds. J Biomed Mater Res A 2008; 86: 796-803.
- 32 Bjerre L, Bunger CE, Kassem M. et al Flow perfusionn culture of human mesenchymal stem cells on silicate-substituted tricalcium phosphate scaffolds. Biomaterials 2008; 29: 2616-2627.
- 33 Grayson WL, Zhao F, Izadpanah R. et al Effects of hyposxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol 2006; 207: 331-339.
- 34 Potier E, Ferreira E, Andriamanalijaona R. et al Hypoxia effects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007; 40: 1078-1087.
- 35 Volkmer E, Kallukalam B, Maertz J. et al Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng A 2010; 16: 153-164.
- 36 Zhao F, Grayson WL, Ma T. et al Perfusion affects the tissue developmental patterns of human mesenchymal stem cells in 3D scaffolds. J Cell Physiol 2009; 219: 421-429.